Purple Biotech competitors & alternatives

Similar biotechnology company

Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.

Similar biotechnology company

Nectin Therapeutics is an Israeli biotechnology company developing cancer immunotherapies that target nectin-family proteins, particularly Nectin-4. Its products are intended for oncology patients and healthcare providers treating solid tumors.

Puma Biotechnology IncPBYI · BiotechnologyLos Angeles, United States

66% matchPublic

Similar biotechnology company

Puma Biotechnology Inc is a biopharmaceutical company that acquires, develops, and commercializes novel therapeutics for the treatment of cancer. The company provides products such as NERLYNX and conducts clinical trials for investigational drugs like alisertib targeting conditions such as small cell lung cancer and metastatic breast cancer.

Quanta Therapies, Inc.BiotechnologyUnited States

66% matchPrivate

Similar biotechnology company

Quanta Therapies is a biopharmaceutical company that develops allosteric small molecule inhibitors targeting RAS-driven cancers, such as pancreatic, colorectal, lung, and endometrial cancers. The company focuses on modulating RAS signaling at the cell membrane to treat previously undruggable mutations like KRAS G12D and KRAS G12V.

Biotech

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Biotech

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine. The company, founded in 2014, was initially known as Imagen Biopharma, Inc. before adopting its current name, Cue Biopharma, Inc., in October 2016. It is headquartered in Cambridge, Massachusetts.

Similar biotechnology company

Creative BioTherapeutics is a biotechnology company that designs first-in-class biologic therapies, notably its lead candidate CBT300, targeting drug-resistant cancers and late-stage viral diseases. The company serves the healthcare and pharmaceutical research sectors by developing non-toxic treatments intended to reverse drug resistance and immune evasion in oncology and infectious diseases.

Similar biotechnology company

Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.

Biotech

PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites. Central to their efforts is Cell-in-a-Box, their proprietary encapsulation technology which utilizes cellulose to enclose live cells. This innovative platform serves as the foundation for treatments aimed at diverse cancers, such as advanced and inoperable pancreatic cancer, as well as diabetes. The company's pipeline includes therapies for pancreatic and other solid cancerous tumors; a treatment for Type 1 and insulin-dependent Type 2 diabetes involving encapsulated, genetically modified insulin-producing cells; and cancer treatments derived from cannabis plant compounds. To further its research, PharmaCyte maintains collaborative agreements: one with the University of Technology, Sydney, for the creation of melligen cells to combat diabetes, and another with the University of Northern Colorado, focusing on methods for identifying, separating, and quantifying cannabis constituents. Originally established in 1996, the company operated under the name Nuvilex, Inc. before rebranding as PharmaCyte Biotech, Inc. in January 2015. Its corporate headquarters are located in Las Vegas, Nevada.

Biotech

Kintor Pharmaceutical Limited, a biotechnology firm in its clinical development phase, is dedicated to the discovery, advancement, and marketing of a diverse array of small molecule and biological therapies. The company primarily concentrates on androgen-receptor-related diseases that represent significant unmet medical needs, serving patients both in the People's Republic of China and globally. Its comprehensive pipeline of investigational products includes: Proxalutamide, a second-generation androgen receptor (AR) antagonist, being explored for the treatment of metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19. Pyrilutamide, another AR antagonist, is under development for androgenetic alopecia (AGA) and acne vulgaris. An ALK-1 antibody targeting metastatic hepatocellular carcinoma (HCC) and various other solid tumors. GT20029, a topical AR-PROTAC compound, designed to address AGA and acne vulgaris. The dual-target antibody PD-L1/TGF-ß, intended for non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. Detorsertib, which is being investigated for metastatic solid tumors such as breast cancer, prostate cancer, and HCC. A Hedgehog/SMO Inhibitor, an agent that blocks the hedgehog signal transduction pathway, aimed at treating blood cancer and basal-cell carcinoma. Founded in 2009, Kintor Pharmaceutical Limited is headquartered in Suzhou, People's Republic of China.

Neotx Holdings Ltd.BiotechnologyIsrael

65% matchPrivate

Similar biotechnology company

Neotx Holdings Ltd. is a biopharmaceutical company that develops cancer therapeutics and immunotherapies. It conducts clinical trials and researches proprietary technologies aimed at advancing cancer treatment.

Biotech

PsyRX CNS Bio-Tech Ltd is dedicated to developing cannabinoid-based pharmaceuticals and healthcare products. Its portfolio encompasses drugs targeting diverse medical conditions, personalized cannabinoid formulations, and CBD-infused skincare along with food supplements. Established in 2019, the company, formerly known as Cannabotech LTD, is headquartered in Rishon LeZion, Israel.